Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

152.55

+3.56 (2.39%)

as of Aug 21, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Aug 22, 2026, 12:00 am

This summary was created by AI, based on 25 opinions in the last 12 months.

Merck & Company (MRK) remains a focal point in the pharmaceutical sector, particularly due to its leading cancer treatment drug, Keytruda, which accounts for a significant portion of its revenue but faces a patent expiration in 2028. Experts note that while revenue growth has been modest in the past few years, recent breakthroughs in cancer trials have generated optimism for the company's potential future. There is a general recognition of Merck's strong pipeline of upcoming drugs, which could help offset the revenue decline anticipated from Keytruda going off-patent. Several experts have recommended strict stop-loss strategies to protect investments while pursuing gains, emphasizing a balance of growth potential and valuation concerns. Overall, the sentiment leans towards cautious optimism as analysts grapple with Merck's future amidst challenges and opportunities.

Consensus

positive

Valuation

fair value

Similar

Pfeizer, PFE

BUY

Outlook for drug companies is good. A bit expensve, but long term is good.

BUY

Sector has been hit hard. At a good level. Prefers Pfizer.

PAST TOP PICK

(Was a top pick on Apr 4 up 1.5%) Still likes.

DON'T BUY

Very reasonable valuation. Patents are coming off. Prefers Pfizer.

DON'T BUY

Fairly cheap. Dividend. Several drugs coming off patent.

BUY

At a 5 year low. Have some good products. At a good price.

WEAK BUY

Expiring patents have created problems. Pipeline is not as strong as other pharmaceuticals, but the price is very cheap.

TOP PICK

One of the cheapest in the drug sctor.

DON'T BUY

Losing a lot of their patents with nothing new in the pipeline.

WEAK BUY

No earnings growth this year. Should be some in 2003. At a good price. Prefers J&J or Pfizer.

DON'T BUY

Broke through a technical base. Generics are giving some tough competition.

DON'T BUY

A lot of their drugs have come off patent without adequate replacement. Prefers Pfizer.

WAIT

Competition. Pipeline is weak now. OK long term.

DON'T BUY

Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot

DON'T BUY

Has been a defensive stock. Overvalued.

Showing 286 to 300 of 310 entries

Most Recent Experts

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Darren Sissons

Campbell Lee & Ross

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Merck & Company (MRK)